Hypoglycemia, Reactive Clinical Trial
— HypoCGMOfficial title:
Evaluation of the Everyday Relevance of Reactive Hypoglycemia in the Oral Glucose Tolerance Test Using Continuous Glucose Measurement.
This research project aims to investigate the everyday relevance of reactive hypoglycemia (hypoglycemia after a glucose load) in the oral glucose tolerance test (OGTT). Therefore, blood glucose profiles in everyday life will be examined using continuous glucose measurement (Free Style Libre PRO IQ system) over a period of 14 days in affected persons.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | December 2024 |
Est. primary completion date | October 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - hypoglycemia during a 75 g oral glucose tolerance test defined as glucose level below 70 mg/dl at timepoint 180 min. - written consent Exclusion Criteria: - diabetes mellitus - use of medication interfering with glucose metabolism (steroid, antidiabetic medications) - surgery of upper GI-tract - known plaster allergies - any other clinical condition that would endanger participants safety or question scientific success according to the physicians opinion |
Country | Name | City | State |
---|---|---|---|
Germany | Universityhospital Ulm | Ulm |
Lead Sponsor | Collaborator |
---|---|
University of Ulm |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurrence of hypoglycemia | Occurrence of glucose levels below 70 mg/dl assessed by CGM. | 14 days | |
Primary | Frequency of hypoglycemia | Number of glucose levels below 70 mg/dl assessed by CGM. | 14 days | |
Primary | Severity of hypoglycemia | Non-severe hypoglycemia defined as glucose levels < 70 mg/dl but >= 54mg/dl; severe hypoglycemia defined as glucose levels < 54mg/dl assessed by CGM. | 14 days | |
Secondary | Time of occurence of hypoglycemia | Occurence of hypoglycemia during day or night time and correspondence to food intake assessed by CGM. | 14 days | |
Secondary | Perception of hypoglycemia | Incidence of typical symptoms of hypoglycemia perceived by the participant, documented in a protocol with free-text fields handed out to the participant during 1st study visit. | 14 days | |
Secondary | Time in predefined glucose ranges | Time spent in the following glucose ranges: time above range: >140mg/dl; time in range: 71-140mg/dl; time below range: <70mg/dl; time with severe hypoglycemia: <54mg/dl assessed by CGM. | 14 days | |
Secondary | Mean glucose levels | Mean glucose levels during monitoring period assessed by CGM. | 14 days | |
Secondary | Glucose variability | Glucose variability during monitoring period assessed by CGM. | 14 days | |
Secondary | Correlation between severity of hypoglycemia during ogtt and hypoglycemia in everyday life | Correlation between severity of hypoglycemia during OGTT and incidence and severity of hypoglycemia in everyday life assessed by CGM. | Varying time point between oGTT and 14 days of glucose assessment using CGM | |
Secondary | Correlation between body composition and hypoglycemia in everyday life | Correlation between body composition (assessed by bioelectrical impedance analysis and anthropometric measurements) and incidence as well as severity of hypoglycemia in everyday life assessed by CGM. | 14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT03514576 -
Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery
|
Phase 4 | |
Completed |
NCT03353415 -
Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety After Gastric Surgery
|
N/A | |
Completed |
NCT05057819 -
Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass
|
Phase 4 | |
Terminated |
NCT04452396 -
CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia
|
N/A |